Boston Children's Hospital has been awarded up to $17.25 million to participate in the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, according to a June 11 announcement. The IMPACT Network is an international initiative funded by Aligning Research to Impact Autism (ARIA), aiming to accelerate the development of treatments for children with profound autism and related neurodevelopmental disabilities, regardless of genetic cause.
The study at Boston Children's will be led by three principal investigators. The IMPACT Network initially consists of 12 clinical sites across the United States, United Kingdom, and Canada that will collaborate on a unified effort to describe development in six different genetic conditions associated with autism—ARID1B, CHD2, GRIN2B, RNU4-2, SCN2A, and SLC6A1—as well as in children with profound autism without an identified genetic cause. By standardizing data collection across all sites, the network aims to address barriers that have historically slowed progress in autism research.
A central objective of this initiative is the creation of a high-quality data resource that will be broadly shared with researchers. Organizers say this level of coordination and transparency is necessary for accelerating scientific progress and ensuring significant impact for affected children and families.
Dr. Siegel said, "This will be the largest study of Profound Autism ever performed and is a historic step in bringing equitable opportunities to our children and families with some of the greatest need." Dr. Faja said, "The commitment to linking objective biological measures with behavior will potentially change the way we understand individual differences and provide clinical care for children with neurodevelopmental conditions."
The award builds on ARIA's previous support for Boston Children's Hospital through grants such as one given to Dr. Mustafa Sahin, who co-leads the Clinical Coordinating Center—the operational core providing both research operations as well as administrative leadership within IMPACT.
Ekemini Riley said, "Building the infrastructure to accelerate therapies for autistic people—particularly those with profound autism—requires exactly the kind of scientific depth and clinical commitment that Boston Children's brings to this network... We are proud to expand our partnership and have Boston Children's join this inaugural wave of the ARIA IMPACT Network as we work to translate scientific discovery into real therapeutic progress."
